CNS Pharmaceuticals (NASDAQ:CNSP) Stock Price Up 1.5% – Here’s Why

Shares of CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) were up 1.5% during mid-day trading on Friday. The company traded as high as $5.40 and last traded at $5.32. 10,901 shares changed hands during trading, an increase of 190% from the average daily volume of 3,759 shares. The stock had previously closed at $5.24.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of CNS Pharmaceuticals in a research note on Friday, July 17th. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the company has an average rating of “Sell”.

CNS Pharmaceuticals Stock Performance

The company has a market cap of $7.77 million, a PE ratio of -0.23 and a beta of 3.10. The firm’s 50 day moving average is $5.47 and its 200-day moving average is $4.60.

CNS Pharmaceuticals (NASDAQ:CNSP) last released its earnings results on Wednesday, August 12th. The company reported ($0.38) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.24) by ($0.14).

Institutional Trading of CNS Pharmaceuticals

An institutional investor recently bought a new stake in CNS Pharmaceuticals stock. Stonepine Capital Management LLC purchased a new stake in shares of CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) during the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The fund purchased 41,573 shares of the company’s stock, valued at approximately $198,719. Stonepine Capital Management LLC owned about 2.85% of CNS Pharmaceuticals at the end of the most recent quarter. 14.02% of the stock is currently owned by institutional investors.

About CNS Pharmaceuticals

CNS Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on developing novel treatments for primary and metastatic cancers of the central nervous system. The company’s research is centered on therapies intended to address the significant challenges associated with treating tumors in the brain and spinal cord, including the blood-brain barrier.

CNS Pharmaceuticals’ lead product candidate is berubicin, an investigational anthracycline designed to cross the blood-brain barrier and reach brain tumors.